


RealRate

PHARMACEUTICAL 2018

XYNOMIC PHARMACEUTICALS HOLDINGS INC. Rank 16 of 349





PHARMACEUTICAL 2018



XYNOMIC PHARMACEUTICALS HOLDINGS INC. Rank 16 of 349

The relative strengths and weaknesses of XYNOMIC PHARMACEUTICALS HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XYNOMIC PHARMACEUTICALS HOLDINGS INC. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 105% points. The greatest weakness of XYNOMIC PHARMACEUTICALS HOLDINGS INC. is the variable Revenues, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 219%, being 496% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	300
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	80
Liabilities, Non-Current	0
Other Assets	62,208
Other Compr. Net Income	0
Other Expenses	365
Other Liabilities	0
Other Net Income	324
Property and Equipment	0
Research and Development	0
Revenues	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	62,508
Liabilities	80
Expenses	365
Stockholders Equity	62,427
Net Income	-41
Comprehensive Net Income	-41
Economic Capital Ratio	219%